

Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Genitourinary Cancers from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Recent planned analysis of prostate irradiation for men with low-volume de novo metastatic hormone-sensitive (HSPC) on the Phase III PEACE-1 trial demonstrated statistically significant improvement in which of the following primary endpoints with the combination of androgen deprivation therapy, abiraterone and prostate radiation therapy?
 - a. Radiographic progression-free survival (rPFS)
 - b. Overall survival (OS)
 - c. Both a and b
 - d. Neither a nor b
2. The Phase III TALAPRO-2 study evaluating talazoparib with enzalutamide versus placebo with enzalutamide as first-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring HRR (homologous recombination repair) gene alterations demonstrated which of the following outcomes with talazoparib/enzalutamide?
 - a. No significant improvement in either rPFS or OS
 - b. Significant improvement in both rPFS and OS
 - c. Significant improvement in rPFS and a trend toward improvement in OS
3. Early results from the ongoing LuPARP trial have reported promising activity and PSA responses with ¹⁷⁷Lu-PSMA-617 in combination with varying doses of which of the following PARP inhibitors for patients with mCRPC?
 - a. Olaparib
 - b. Niraparib
 - c. Rucaparib
 - d. Talazoparib
4. Analysis of the Phase III CONTACT-03 trial evaluating the efficacy and safety of atezolizumab with cabozantinib versus cabozantinib alone after disease progression with prior immune checkpoint inhibitor treatment for patients with metastatic renal cell carcinoma reported significant improvement in which of the following endpoints with the combination therapy?
 - a. rPFS
 - b. OS
 - c. Both a and b
 - d. Neither a nor b
5. Post hoc analysis of data from the Phase III IMvigor130 trial evaluating OS by response to first-line induction treatment with atezolizumab and platinum/gemcitabine versus placebo and platinum/gemcitabine for patients with metastatic urothelial bladder cancer reported that initial response to induction therapy _____ to affect OS.
 - a. Did not seem
 - b. Seemed